Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.

Daisuke SakaiTakeshi OmoriSoichi FumitaJunya FujitaRyohei KawabataJin MatsuyamaHisateru YasuiMotohiro HiraoTomono KawaseKentaro KishiYoshiki TaniguchiYasuhiro MiyazakiJunji KawadaHironaga SatakeTomoko MiuraAkimitsu MiyakeYukinori KurokawaMakoto YamasakiTomomi YamadaTaroh SatohHidetoshi EguchiYuichiro Doki

Published in: International journal of clinical oncology (2022)

The observed OS in this study for HER2-positive G/GEJ cancer was shorter than that reported previously, suggesting that the effectiveness of nivolumab, irinotecan, or FTD/TPI as 3L + therapy may be limited.

Keyphrases

randomized controlled trial
systematic review
squamous cell carcinoma
papillary thyroid
small cell lung cancer
stem cells
radiation therapy
young adults
combination therapy